Take the hair concern somewhere it can be assessed.
A hair concern deserves a conversation about your hair, not just an ingredient. We’d keep two questions together: what’s causing the change, and what do we know about anything proposed for it? Neither a hopeful study nor a reassuring label can finish that conversation.
Put the hair question first
A dermatologist or licensed U.S. clinician can assess a hair concern. A licensed telehealth service that can prescribe is another route. That conversation can cover treatment, including FDA-approved options where they exist.
You can bring the claim that caught your attention without arriving with a diagnosis. To check a physician’s licence, the state medical board directory points to the board itself. A licence check doesn’t guarantee an outcome.
A cosmetic label doesn’t settle a treatment claim
FDA looks at intended use: what something is meant to do. Improving appearance is different from claiming to treat disease or change how the body works. A skincare ingredient doesn’t become a proven hair-loss medicine because its name is familiar.
The FDA application search recorded on September 30, 2026 found no approved GHK-Cu medicine. We’re describing the U.S. rules in general here, rather than deciding the legal status of a particular item.
Lotion research can’t answer injection questions
On FDA’s page current as of April 22, 2026, injectable GHK-Cu is ‘nominated but withdrawn’: the request to consider it was taken back. FDA still raises concerns about immune reactions linked to clumping and impurities, with limited human safety data. Withdrawal isn’t clearance, approval or Category 1. FDA gives no withdrawal date for the entry.
GHK-Cu that isn’t injected has a separate entry on the 503A Category 1 list updated May 14, 2026, for substances under review. FDA says it doesn’t intend to act against a compounder for using a listed bulk ingredient when the policy’s conditions are met. It isn’t FDA approval or a blanket statement that compounding is lawful.
Compounding means preparing a medicine for a patient’s particular needs. Compounded medicines aren’t FDA-approved. A prescription, a place on that list and FDA approval mean different things. One doesn’t substitute for another.
A few questions can keep the visit focused
What kind of hair loss are we discussing? Was the proposed approach studied in people with it? Did the study use the same ingredient in the same way? What do we still not know about safety over time?
This guide gives general information, not medical advice. We give no doses or mixing instructions. A licensed clinician can discuss your circumstances and appropriate care; a page about research can’t assess your scalp or decide what’s suitable.
Our references collect the papers and FDA records. The contact page explains what this guide can handle.